Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • News
    • Anesthesiology
    • DAPT with aspirin...

    DAPT with aspirin prevents saphenous vein graft failure in CABG, finds BMJ study

    Written by Dr. Kamal Kant Kohli Kohli Published On 2019-10-13T20:30:10+05:30  |  Updated On 13 Oct 2019 8:30 PM IST
    DAPT with aspirin prevents saphenous vein graft failure in CABG, finds BMJ study

    Canada: Aspirin is the preferred antiplatelet drug for the prevention of saphenous vein graft failure in patients undergoing coronary artery bypass graft. Now, a meta-analysis published in the BMJ journal has shown the dual antiplatelet therapy (DAPT) with ticagrelor or clopidogrel to be superior to aspirin for the said purpose.


    Patients with multivessel coronary artery disease are treated with coronary artery bypass grafting (CABG). But patients undergoing this procedure are at risk of subsequent major adverse cardiovascular events (MACE), causes mainly by the associated progression of saphenous vein graft failure, vascular damage or native coronary artery disease.


    According to the authors, saphenous vein graft has high early failure rates, despite this, it remains the most commonly used graft in contemporary coronary artery bypass graft trials.


    Karla Solo, clinical epidemiologist, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada, and colleagues assessed the effects of different oral antithrombotic drugs that prevent saphenous vein graft failure in patients undergoing CABG.


    The analysis included 20 randomised controlled trials of participants (aged ≥18) who received oral antithrombotic drugs (antiplatelets or anticoagulants) to prevent saphenous vein graft failure after coronary artery bypass graft surgery. Some 4800 adults who received saphenous grafts were included; follow-up ranged from 1 month to 8 years.


    The primary efficacy endpoint was saphenous vein graft failure and the primary safety endpoint was major bleeding. Secondary endpoints were myocardial infarction and death.


    Key findings include:

    • Compared with aspirin monotherapy, DAPT with aspirin plus ticagrelor was associated with reduced risk for venous graft failure (odds ratio, 0.5), as was aspirin plus clopidogrel (OR, 0.6).

    • The researchers calculated that 10 patients would need to receive aspirin plus ticagrelor or 19 would need to receive aspirin plus clopidogrel to prevent one graft failure.

    • The risk for major bleeding did not differ significantly across active drug interventions.


    "Our results suggest an important absolute benefit of ticagrelor or clopidogrel addition to aspirin for the prevention of saphenous vein graft failure after CABG. Dual antiplatelet therapy should be administered to patients undergoing CABG only after balancing the safety and efficacy profile of the drug intervention against important patient outcomes," write the authors.


    "Future guideline updates are needed to optimise antithrombotic management of patients undergoing coronary artery bypass graft surgery. Meanwhile, dual antiplatelet therapy with aspirin plus ticagrelor or aspirin plus clopidogrel could be considered for most patients after surgery," they concluded.




    More Information: "Antithrombotic treatment after coronary artery bypass graft surgery: a systematic review and network meta-analysis" published in The BMJ journal


    DOI: https://doi.org/10.1136/bmj.l5476

    Journal Information: The BMJ
    antiplatelet drugaspirinBMJCABGClopidogrelcoronary artery bypass graft surgerycoronary artery bypass graftingCoronary artery diseaseDAPTdual antiplatelet therapyKarla Solosaphenous graftssaphenous vein graft failureticagrelor
    Source : With inputs from the BMJ

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Dr. Kamal Kant Kohli Kohli
    Dr. Kamal Kant Kohli Kohli
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok